Clinical experience with nanoparticle albumin-bound paclitaxel, a novel taxane anticancer agent, and management of adverse events in females with breast cancer

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is currently approved in Japan for treatment of breast cancer. However, apart from phase I clinical trials, data regarding Japanese patients are scant. In the present study, the efficacy and safety of nab-paclitaxel therapy were retrospectively...

Descripción completa

Detalles Bibliográficos
Autores principales: TAKASHIMA, SEIKI, KIYOTO, SACHIKO, TAKAHASHI, MINA, HARA, FUMIKATA, AOGI, KENJIRO, OHSUMI, SHOZO, MUKAI, RYOKO, FUJITA, YORIKO
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356397/
https://www.ncbi.nlm.nih.gov/pubmed/25789050
http://dx.doi.org/10.3892/ol.2015.2954

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356397/
https://www.ncbi.nlm.nih.gov/pubmed/25789050
http://dx.doi.org/10.3892/ol.2015.2954

Ejemplares similares